Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. develops and commercializes molecular diagnostic tests used to guide care in dermatologic and gastroenterological disease. Its recurring updates focus on test report volume, revenue performance, guidance, and clinical evidence for products such as DecisionDx-Melanoma and TissueCypher.
Company news also covers studies, publications, and medical-meeting presentations involving risk stratification for cutaneous melanoma, sentinel lymph node biopsy decision support through DecisionDx-Melanoma’s i31-SLNB result, and Barrett’s esophagus progression-risk assessment with TissueCypher. Financial releases frequently discuss core revenue drivers, reimbursement effects, commercial focus, and quarterly operating results.
Castle Biosciences (Nasdaq: CSTL) published a prospective multicenter study in Future Oncology showing DecisionDx-Melanoma’s i31-SLNB identifies patients below the NCCN 5% threshold for forgoing SLNB. Key results: 2.6% observed SLN positivity overall for 5% predicted patients; in T1b–T2a; 97.8% three-year RFS in low-risk patients. The i31-SLNB produced TN:FN ratios of 55:1 (T1–T2a) and 73:1 (T1b–T2a), exceeding the 19:1 guideline benchmark. A webcast will be held March 23, 2026, to discuss the data.
Castle Biosciences (Nasdaq: CSTL) reported prospective multicenter results showing DecisionDx-Melanoma’s i31-SLNB accurately predicts sentinel lymph node (SLN) positivity and identifies low-risk patients. In 912 patients across 30 U.S. centers, those with 5% predicted risk had a 2.6% actual SLN positivity rate and 97.8% three-year recurrence-free survival.
Castle Biosciences (Nasdaq: CSTL) will present data at SSO 2026 (March 5–7, 2026) showing DecisionDx-Melanoma’s i31-SLNB algorithm predicts sentinel lymph node (SLN) positivity and may identify T1b–T2a melanoma patients who can safely avoid SLNB. The ePoster (EP49) reports independent validation of an integrated 31‑gene expression profile with clinicopathologic factors to provide personalized SLN risk estimates and support risk‑aligned decision-making.
ePosters will be available in the SSO Exhibit Hall, on the meeting website and in the SSO mobile app; Castle will be at booth #321.
Castle Biosciences (Nasdaq: CSTL) will host a grand opening for its new corporate headquarters in Friendswood, Texas on March 24, 2026 at 3:00 p.m. CT. The purpose-built 23-acre campus features energy-efficient systems, storm-rated design, flexible workspaces and employee amenities.
The facility supports Castle’s clinical testing operations and growth as the company advances its molecular test portfolio; Castle reported $344 million revenue in 2025. The event is by invitation; media may RSVP in advance.
Castle Biosciences (Nasdaq: CSTL) reported full-year 2025 revenue of $344.2M, exceeding guidance, with core test report volumes up sharply. Core tests (DecisionDx-Melanoma, TissueCypher) grew 37% year-over-year; TissueCypher test reports rose 86% in 2025. The company ended 2025 with $299.5M in cash and marketable securities and provided 2026 revenue guidance of $340M–$350M.
Notable items include a one-time $20.1M accelerated amortization adjustment, the discontinuation of IDgenetix in May 2025, and a Medicare coverage change for DecisionDx-SCC effective April 24, 2025.
Castle Biosciences (Nasdaq: CSTL) reported a prospective multicenter validation in JAAD showing its AdvanceAD-Tx test stratifies moderate-to-severe atopic dermatitis patients by molecular profile to predict response to JAK inhibitor therapy.
About 30% of patients were classified as a JAK Inhibitor Responder Profile; those treated with a JAKi were 5.5x more likely to reach EASI-90 by three months (45.5% vs 8.3%, p=0.021) and achieved responses nearly four times faster (p=0.049). Results also showed higher vIGA-AD clear rates, itch resolution, flare-free status, and DLQI 0 in the JAK responder subgroup.
Castle Biosciences (Nasdaq: CSTL) will release fourth-quarter and full-year 2025 financial results after market close on Thursday, Feb. 26, 2026. Management will host a conference call and webcast at 4:30 p.m. Eastern the same day with a brief Q&A and a replay available.
Castle Biosciences (Nasdaq: CSTL) reported preliminary, unaudited results for Q4 and full-year 2025. 2025 total revenue is expected to exceed $340 million, above prior guidance of $327–$335 million. Core test reports (DecisionDx-Melanoma and TissueCypher) rose 37% year-over-year for 2025 and 42% in Q4. TissueCypher Barrett’s Esophagus reports doubled to 39,014 in 2025. Castle launched AdvanceAD-Tx on limited access in Nov 2025; >50% of ~150 clinician offices ordered within five weeks. Year-end cash and marketable securities are expected to total approximately $300 million ($116M cash; $184M marketable securities). The company cited an April 24, 2025 Medicare coverage change that affected some test volumes and commercial focus.
Castle Biosciences (Nasdaq: CSTL) announced that on Dec. 15, 2025 its Compensation Committee granted restricted stock units to 83 employees covering an aggregate of 139,494 shares as inducements for entering employment.
The grants were made under the company’s 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years: 25% on the first anniversary of each applicable vesting commencement date, then the remaining shares vest annually in three equal installments, subject to continued service through each vesting date.
Castle Biosciences (Nasdaq: CSTL) reported new data from the largest prospective, multicenter study comparing NGS-based mutation analysis with the combination of DecisionDx-UM + PRAME for predicting outcomes in uveal melanoma (UM). Published Dec. 17, 2025, the COOG study analyzed 1,140 primary UM tumors and found that DecisionDx-UM + PRAME provided superior predictions of metastasis-free survival (MFS) and overall survival (OS) versus individual NGS mutation analysis. BAP1, SF3B1 and EIF1AX mutations lost independent predictive significance when DecisionDx-UM + PRAME were included in multivariate models. Castle offers DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq from one biopsy to support risk stratification and treatment planning.